| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
BioNexus Gene Lab Corp. ("BGLC, ("BGLC," NASDAQ:BGLC) today announced it has entered into definitive agreements with Fidelion Diagnostics Pte. Ltd. ("Fidelion") and Tongshu Biotechnology (Hong Kong) Co., Limited ("Tongshu"), among other parties, to commercialize VitaGuard™, a high-fidelity, tumor-naïve liquid-biopsy platform for minimal residual disease (MRD).
The parties executed a Share Subscription and Shareholders' Agreement aligning ownership and governance around a rapid Southeast Asia rollout.
The collaboration is intended to support the development and planned commercialization of MRD testing in Southeast Asia through aligned ownership, licensing and operational support.
Just as the sub-$1,000 genome unlocked mainstream sequencing, BGLC, Fidelion, and Tongshu aim to deliver the same cost-curve collapse for MRD.
Posted In: BGLC
